Marshall Wace
TRDA icon

Marshall Wace’s Entrada Therapeutics TRDA Stock Holding History

Marshall Wace’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-53,764
Closed -$679K – 3762
2026
Q1 		$679K Buy
53,764
+33,107
+160% +$379K ﹤0.01% 2317
2025
Q4 		$212K Buy
+20,657
New +$174K ﹤0.01% 2577
2024
Q4 		– Sell
-100,106
Closed -$1.6M – 3011
2024
Q3 		$1.6M Buy
100,106
+34,163
+52% +$538K ﹤0.01% 1448
2024
Q2 		$940K Buy
65,943
+14,220
+27% +$202K ﹤0.01% 1718
2024
Q1 		$733K Buy
+51,723
New +$731K ﹤0.01% 1779
2023
Q3 		– Sell
-11,312
Closed -$171K – 2688
2023
Q2 		$171K Sell
11,312
-6,015
-35% -$82.9K ﹤0.01% 2264
2023
Q1 		$251K Buy
+17,327
New +$231K ﹤0.01% 2350

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Marshall Wace's TRDA Position: Q2 2026 in Review

Marshall Wace sold out of Entrada Therapeutics (TRDA) in Q2 2026, closing a stake of 53,764 shares — an estimated $679K sold.

Marshall Wace first reported a position in TRDA in Q1 2023 and held it in 7 quarters. The position peaked at $1.6M in Q3 2024. 129 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Marshall Wace reported no remaining Entrada Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Marshall Wace sold 53,764 Entrada Therapeutics shares in Q2 2026, an estimated $679K.
  • Marshall Wace first reported a position in Entrada Therapeutics in Q1 2023 and held it in 7 quarters.
  • Marshall Wace's Entrada Therapeutics position peaked at $1.6M in Q3 2024.
  • 129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.